ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers

UF startup ViewRay, Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced the publication by the European Urology Oncology Journal of a prospective phase II study of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer.

The publication is a follow-up to early outcomes published in 2019 which reported low incidence of acute toxicity in both clinician- and patient-reported outcomes. The one-year data reported continued absence of grade 3 or higher toxicities and reductions in long-term patient-reported outcome measures after MRIdian treatment. Researchers from Amsterdam University Medical Centers enrolled 101 patients and the study is one of the first to research SBRT in a mix of intermediate- and high-risk prostate cancer patients, a population that is challenging to treat. The journal is the official scientific journal of the European Association of Urology.

Learn more about ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers.